Regeneron Pharmaceuticals, Inc. (LON:0R2M)
546.04
-2.27 (-0.41%)
At close: Aug 1, 2025
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.68B USD in the quarter ending June 30, 2025, with 3.62% growth. This brings the company's revenue in the last twelve months to $14.21B, up 5.38% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.21B
Revenue Growth
+5.38%
P/S Ratio
4.22
Revenue / Employee
$940.96K
Employees
15,106
Market Cap
43.75B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Regeneron Pharmaceuticals News
- 4 days ago - 5 Stocks That Launched New Dividends In This Roller-Coaster Market - Forbes
- 9 days ago - Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation - GlobeNewsWire
- 10 days ago - ANI Pharma drops as clinical trial for eye implant fails against Regeneron’s Eylea - Seeking Alpha
- 21 days ago - SA analyst upgrades/downgrades: CVX, TLRY, LULU, REGN - Seeking Alpha
- 23 days ago - Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025 - Seeking Alpha
- 24 days ago - Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug - Benzinga
- 4 weeks ago - Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment - WSJ
- 4 weeks ago - Regeneron wins FDA accelerated nod for multiple myeloma therapy - Seeking Alpha